Skip to main content
Premium Trial:

Request an Annual Quote

People: Byron Hewett, Larry Gold


SomaLogic has named Byron Hewett as CEO. Hewett takes replaces Larry Gold, who will continue serving the Boulder, Colo.-based company as chairman of the board. Gold will also work as a full-time adviser, SomaLogic said.

Gold co-founded SomaLogic in 2000 and had served as CEO until Hewett's appointment. In a statement, Gold said that while the protein biomarker discovery and clinical diagnostics company has been successful in its initial goals, it needed "additional leadership with the deep business experience and knowledge to take SomaLogic to the next level," and that Hewett is "the leader we need at this critical stage of our company's growth."

Hewett most recently was chairman and CEO of Biobehavioral Diagnostics. He previously was president and CEO of Immunicon and senior vice president of sales and marketing and general manager, North America, for Qiagen. He also has held leadership posts at Abbott Diagnostics, Chiron/Bayer, and BioCircuits.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.